140 related articles for article (PubMed ID: 17322917)
1. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans.
Bond GL; Levine AJ
Oncogene; 2007 Feb; 26(9):1317-23. PubMed ID: 17322917
[TBL] [Abstract][Full Text] [Related]
2. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
3. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.
Hu W; Feng Z; Ma L; Wagner J; Rice JJ; Stolovitzky G; Levine AJ
Cancer Res; 2007 Mar; 67(6):2757-65. PubMed ID: 17363597
[TBL] [Abstract][Full Text] [Related]
4. Shaping genetic alterations in human cancer: the p53 mutation paradigm.
Soussi T; Wiman KG
Cancer Cell; 2007 Oct; 12(4):303-12. PubMed ID: 17936556
[TBL] [Abstract][Full Text] [Related]
5. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
[TBL] [Abstract][Full Text] [Related]
7. Common genetic variants in the TP53 pathway and their impact on cancer.
Barnoud T; Parris JLD; Murphy ME
J Mol Cell Biol; 2019 Jul; 11(7):578-585. PubMed ID: 31152665
[TBL] [Abstract][Full Text] [Related]
8. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
10. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
11. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
Lahiri O; Harris S; Packham G; Howell M
Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
13. Single-nucleotide polymorphisms in the p53 signaling pathway.
Grochola LF; Zeron-Medina J; Mériaux S; Bond GL
Cold Spring Harb Perspect Biol; 2010 May; 2(5):a001032. PubMed ID: 20452958
[TBL] [Abstract][Full Text] [Related]
14. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
15. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.
Bartel F; Jung J; Böhnke A; Gradhand E; Zeng K; Thomssen C; Hauptmann S
Clin Cancer Res; 2008 Jan; 14(1):89-96. PubMed ID: 18172257
[TBL] [Abstract][Full Text] [Related]
16. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
17. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang P; Kitchen-Smith I; Xiong L; Stracquadanio G; Brown K; Richter PH; Wallace MD; Bond E; Sahgal N; Moore S; Nornes S; De Val S; Surakhy M; Sims D; Wang X; Bell DA; Zeron-Medina J; Jiang Y; Ryan AJ; Selfe JL; Shipley J; Kar S; Pharoah PD; Loveday C; Jansen R; Grochola LF; Palles C; Protheroe A; Millar V; Ebner DV; Pagadala M; Blagden SP; Maughan TS; Domingo E; Tomlinson I; Turnbull C; Carter H; Bond GL
Cancer Res; 2021 Apr; 81(7):1667-1680. PubMed ID: 33558336
[TBL] [Abstract][Full Text] [Related]
18. The importance of p53 pathway genetics in inherited and somatic cancer genomes.
Stracquadanio G; Wang X; Wallace MD; Grawenda AM; Zhang P; Hewitt J; Zeron-Medina J; Castro-Giner F; Tomlinson IP; Goding CR; Cygan KJ; Fairbrother WG; Thomas LF; Sætrom P; Gemignani F; Landi S; Schuster-Böckler B; Bell DA; Bond GL
Nat Rev Cancer; 2016 Apr; 16(4):251-65. PubMed ID: 27009395
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect.
Bond GL; Hu W; Levine A
Cancer Res; 2005 Jul; 65(13):5481-4. PubMed ID: 15994915
[TBL] [Abstract][Full Text] [Related]
20. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
